治疗湿性年龄相关性黄斑变性新药:brolucizumab  

A new drug in treatment of wet age-related macular degeneration:brolucizumab

作　　者：孙韬华[1] 刘振胜[1] 刘杰[1] SUN Tao-hua;LIU Zhen-sheng;LIU Jie(Department of Pharmacy,Qingdao Municipal Hospital,Qingdao SHANDONG 266011,China)

机构地区：[1]青岛市市立医院药学部,山东青岛266011

出　　处：《中国新药与临床杂志》2020年第9期523-526,共4页Chinese Journal of New Drugs and Clinical Remedies

基　　金：青岛市2018年度医药科研指导计划(2018-WJZD010)。

摘　　要：brolucizumab属人源化的单克隆单链Fv抗体片段,是人血管内皮生长因子抑制剂。美国食品和药物管理局于2019年10月批准brolucizumab用于湿性年龄相关性黄斑变性的治疗。单次玻璃体腔内注射brolucizumab约24 h后达血清峰浓度,全身消除半衰期约为4.4 d。临床研究表明,与阿柏西普相比,brolucizumab对最佳矫正视力的改善呈非劣效性,且brolucizumab的疗效更为稳定,能更好地降低视网膜中心区厚度,减少组织积液,并可维持较长的给药间隔。brolucizumab常见不良反应包括视力模糊、白内障和结膜出血等。Brolucizumab is a humanized monoclonal single-chain Fv antibody fragment and a human vascular endothelial growth factor inhibitor.It was approved for the treatment of wet age-related macular degeneration by the U.S.Food and Drug Administration in October,2019.The serum cmax of brolucizumab was reached about 24 hours after single intravitreal injection,and the half-life of systemic elimination was about 4.4 days.Clinical studies have shown that brolucizumab demonstrated noninferiority to aflibercept in best-corrected visual acuity change,and the efficacy of brolucizumab is more stable.It can better reduce the thickness of the central area of the retina,reduce the tissue effusion,and can maintain a longer dosing interval.The common adverse reactions of brolucizumab include vision blurred,cataract,conjunctival hemorrhage,and so on.

关 键 词：brolucizumab 黄斑变性 血管内皮生长因子 临床研究 

分 类 号：R774.5[医药卫生—眼科]